DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell–mediated antitumor immunity.

MLA

Wichroski, Michael, et al. “DGKα/ζ Inhibitors Combine with PD-1 Checkpoint Therapy to Promote T Cell–mediated Antitumor Immunity.” Science Translational Medicine, vol. 15, no. 719, Oct. 2023, pp. 1–15. EBSCOhost, https://doi.org/10.1126/scitranslmed.adh1892.

APA

Wichroski, M., Benci, J., Liu, S.-Q., Chupak, L., Fang, J., Cao, C., Wang, C., Onorato, J., Qiu, H., Shan, Y., Banas, D., Powles, R., Locke, G., Witt, A., Stromko, C., Qi, H., Zheng, X., Martin, S., Ding, M., & Gentles, R. (2023). DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell–mediated antitumor immunity. Science Translational Medicine, 15(719), 1–15. https://doi.org/10.1126/scitranslmed.adh1892

Chicago

Wichroski, Michael, Joseph Benci, Si-Qi Liu, Louis Chupak, Jie Fang, Carolyn Cao, Cindy Wang, et al. 2023. “DGKα/ζ Inhibitors Combine with PD-1 Checkpoint Therapy to Promote T Cell–mediated Antitumor Immunity.” Science Translational Medicine 15 (719): 1–15. doi:10.1126/scitranslmed.adh1892.